Compare · LGVN vs NVS
LGVN vs NVS
Side-by-side comparison of Longeveron Inc. (LGVN) and Novartis AG (NVS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LGVN and NVS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVS is the larger of the two at $305.27B, about 14080.7x LGVN ($21.7M).
- Over the past year, LGVN is down 13.1% and NVS is up 24.5% - NVS leads by 37.6 points.
- LGVN has hit the wire 24 times in the past 4 weeks while NVS has been quiet.
- NVS has more recent analyst coverage (25 ratings vs 2 for LGVN).
- Company
- Longeveron Inc.
- Novartis AG
- Price
- $0.71+4.46%
- $157.83-1.36%
- Market cap
- $21.7M
- $305.27B
- 1M return
- +18.37%
- -1.27%
- 1Y return
- -13.05%
- +24.52%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 24
- 0
- Recent ratings
- 2
- 25
Longeveron Inc.
Longeveron Inc., a clinical stage biotechnology company, engages in developing cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications comprising aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is headquartered in Miami, Florida.
Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Latest LGVN
- Chief Financial Officer Jhaveri Nirav S. was granted 300,000 shares (SEC Form 4)
- New insider Jhaveri Nirav S. claimed no ownership of stock in the company (SEC Form 3)
- Longeveron Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits
- Longeveron Announces 1-for-10 Reverse Stock Split
- Chief Medical Officer Agafonova Nataliya was granted 286,000 shares, increasing direct ownership by 66% to 716,914 units (SEC Form 4)
- CTO & SVP of CMC Blass Devin was granted 286,000 shares, increasing direct ownership by 67% to 711,735 units (SEC Form 4)
- Chief Scientific Officer Hare Joshua was granted 286,000 shares, increasing direct ownership by 22% to 1,607,796 units (SEC Form 4)
- Director Ascheim Deborah was granted 36,000 shares (SEC Form 4)
- Director Cann Leah Rush was granted 36,000 shares (SEC Form 4)
- Director Soffer Rock was granted 36,000 shares, increasing direct ownership by 16% to 262,034 units (SEC Form 4)
Latest NVS
- SEC Form 6-K filed by Novartis AG
- The Quest to Repair What Multiple Sclerosis Takes Away
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- Novartis AG upgraded by Argus with a new price target
- Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy
- SEC Form S-8 filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG